Press Releases
May 12, 2020
Summary ToggleIntellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia’s CRISPR/Cas9 proprietary process produces multiple, highly efficient sequential edits in T cells that have superior function and minimal translocations, compared to results from standard T cell engineering approaches Proprietary process supports NTLA-5001 and other potential therapies for
May 7, 2020
Summary ToggleIntellia Therapeutics Announces First Quarter 2020 Financial Results
On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H 2020 On track to submit an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001 for the treatment of acute myeloid leukemia, in 1H 2021
Apr 30, 2020
Summary ToggleIntellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer
CAMBRIDGE, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl , M.D., as its new executive vice president and chief medical officer. Dr. Lebwohl brings decades of biopharmaceutial leadership and drug development experience, and joins
Apr 30, 2020
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates
CAMBRIDGE, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its first quarter 2020 financial results and operational
Apr 28, 2020
Summary ToggleIntellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
Company to Present Three Oral and Two Poster Presentations on In Vivo and Engineered Cell Therapy Pipeline Programs CAMBRIDGE, Mass. , April 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using
Mar 31, 2020
Summary ToggleFDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics
CAMBRIDGE, Mass. , March 31, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced that the U.S.
Feb 27, 2020
Summary ToggleIntellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results
On track to submit an IND application for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020 and to dose first patients in 2H 2020 Plans to submit an IND application for NTLA-5001, a WT1-directed TCR-T cell therapy, for the treatment of acute myeloid leukemia in 1H 2021 Expects to
Feb 20, 2020
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2019 Earnings and Company Update
CAMBRIDGE, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present fourth quarter and full-year 2019 financial results and
Feb 10, 2020
Summary ToggleIntellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference
Specific and potent tumor cell killing observed in WT1-positive acute myeloid leukemia blasts in vitro by TCR-based engineered T cells, supporting Intellia’s first engineered T cell therapy development candidate, NTLA-5001 Knockout of KLKB1 gene with CRISPR/Cas9 for hereditary angioedema results in
Jan 9, 2020
Summary ToggleIntellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones
On track to submit IND application for lead candidate, NTLA-2001 for transthyretin amyloidosis, in mid-2020 and dose first patients in 2H 2020 Nominated NTLA-5001 for the treatment of acute myeloid leukemia as first WT1-TCR-directed engineered cell therapy development candidate; plan to submit IND
